Hematology and Oncology
Dr. Elyse Watkins
Advances in Triple-Negative Breast Cancer Treatment
The purpose of this article is to explore the advancements in triple-negative breast cancer (TNBC) and review the current and the new potential emerging approaches to treat TNBC.
An online database search of PubMed and Google Scholar was conducted using search terms breast cancer, triple-negative breast cancer, TNBC, HER-2 negative, and TNBC advances to identify clinical trials, randomized controlled trials, as well as review articles. Fifty-seven relevant articles were identified for this clinical review article.
The recent research advances in TNBC treatment demonstrate promising results, with several novel targeted agents being used as monotherapy or in combination with chemotherapy or other targeted agents.
Due to the lack of therapeutic targets for estrogen (ER) receptor, progesterone (PR) receptor, and human epidermal growth factor receptor-2 (HER-2) in TNBC, there are no targeted therapies to be used against these receptors. With the identification of mutations in the signaling pathways, several new targeted agents are being developed. The current research in identifying new agents and developing new treatment methods with combination strategies seems promising; however, research needs to continue to establish long-term effectiveness.
Breast cancer, Triple negative breast cancer, TNBC, HER-2 negative, TNBC advances.
Singh G, Watkins E. Advances in Triple-Negative Breast Cancer Treatment. Lynchburg Journal of Medical Science. 2021; 3(4).
Available when accessing via a campus IP address or logged in with a University of Lynchburg email address.
Off-campus users can also use 'Off-campus Download' button above for access.